



NiKem Research Srl receives the approval from the French Ministry of Research as a “Crédit d’Impôt Recherche” (C.I.R.) Certified Company (August 4th, 2008)

Baranzate (MI) Italy, August 4th 2008 - NiKem Research Srl, an international service provider in the field of Drug Discovery based in Italy, announced today that the French Ministry of Research (FMR) has accepted the company's request to be included in the list of FMR-approved contract research organizations (CROs) carrying out R&D activities for French private companies. This approval, which is valid for the three year period between 2008 and 2010 and could be renewed afterwards, entitles and will entitle any French private company to claim significant tax credit (“Crédit d’Impôt Recherche”, C.I.R.) for R&D activities executed by NiKem Research on their behalf in the above mentioned time period.

More details on C.I.R., on its structure, and on the procedures for obtaining tax credit by eligible companies are reported at:

<http://www.enseignementsup-recherche.gouv.fr/cid20358/le-credit-d-impot-recherche-cir.html>

A list of approved CROs, which shortly will also include NiKem Research, can be accessed at:

<http://www.enseignementsup-recherche.gouv.fr/cid21100/recherche-sous-traitee.html>

NiKem Research has a long standing history of successful collaborations with French companies active in the pharmaceutical sector, such as Servier and Hybrigenics.

NiKem believes that its C.I.R. certification may now allow a further expansion of business relationships with French companies, and is committed to provide an extremely cost-effective support to any interested French partner.

Giuseppe Giardina, CEO & Managing Director of NiKem, said: "The approval as a C.I.R. certified company by the French Ministry of Research is an important step forward for NiKem. We believe that our already significant business volume with French pharmaceutical and, most importantly, biotech companies will grow: in fact, our high quality standards are now combined with competitive prices and tax credit options. Thus, we expect to at least double our revenues in France in the next three years."

About NiKem Research

Based on decades of drug discovery experience and now operating at biotech speed, NiKem Research offers a full range of Drug Discovery services to the pharmaceutical industry. In addition to its expertise in medicinal chemistry related to hit validation, prioritization and multiparametric lead optimization, NiKem Research has chemical skills and parallel synthesis capabilities, and may provide also computational and analytical chemistry services. Furthermore, ADMET profiling, biochemical screening and in vivo PK services can be provided either as an integrated Drug Discovery platform, or as single, independent modules. NiKem Research usually operates as a classical fee-for-service partner, and all tangible and intangible assets generated during a collaboration are assigned to the client.

Media Contact:

NiKem Research Srl

Samadhi Battistoni

Tel. +39 02 35694 7050

Fax +39 02 35694 7606

Samadhi.battistoni@nikemresearch.com